|Bid||193.00 x 100|
|Ask||198.90 x 100|
|Day's range||205.37 - 213.70|
|52-week range||73.95 - 222.03|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Bagging the first breakthrough therapy designation for a sickle cell disease modifying treatment boosted confidence last month.
Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.
The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth. Sanofi agreed to buy U.S. haemophilia expert Bioverativ (BIVV.O) for $11.6 billion, its biggest deal for seven years, while Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics (JUNO.O) it does not already own.
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
Juno is now the cheapest CAR-T player, an analyst said Wednesday as he downgraded rival Bluebird on a lack of catalysts until the spring.
A next-generation cancer treatment could significantly change multiple myeloma outcomes for thousands of people, generating hundreds of millions of dollars in sales for the company.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.